Earnings call transcript: Orkla’s Q1 2026 results show solid growth

Orkla reported Q1 2026 revenue of NOK 17.4 billion, up 1.3% year-over-year, with organic growth of 4.9% and adjusted EPS up 4% to NOK 1.75. Underlying EBITDA fell 1.3% due to currency effects, while shares dropped 6.59% pre-market on concerns about rising input costs, FX pressure, and restructuring at Orkla Health. Management said the Middle East conflict is creating uncertainty for freight, energy, and packaging costs, but still expects continued organic growth and is using price increases and alternative sourcing to offset pressure.

Analysis

The market is treating this as a margin-reset story, but the more important signal is that Orkla’s portfolio is now behaving like a barbell: Jotun and Snacks/Ingredients are still compounding, while Health is becoming a capital sink that can mask the rest. That creates a second-order opportunity in the equity: the conglomerate discount should widen when one division is in a multi-quarter remediation cycle and another is about to absorb raw-material inflation, even if reported top-line stays resilient.

The key catalyst is not Q1 itself; it is the timing mismatch between price increases and cost realization. Management is signaling that inflation will hit progressively through the year, which means Q2 can still look deceptively fine while margin compression accelerates into H2 as procurement catch-ups and freight/energy pass-throughs lag. That makes near-term consensus too optimistic on earnings quality, especially if Easter timing reverses in Q2 and the “good” volume mix from Q1 proves partly transitory.

The market is also underestimating how the Health restructuring changes capital allocation. Closing plants creates a multi-quarter drag from duplicate costs, but it also telegraphs that management is willing to sacrifice near-term optics to rebuild long-term ROIC; that is good governance, yet near-term reported EPS may be less relevant than cash conversion and stranded-cost visibility. The real upside optionality sits in Jotun’s pricing power, but the downside tail is a sharper-than-expected input-cost spike if geopolitical disruption extends into marine/protective coatings and freight, where the pass-through cycle is slower than the cost cycle.

Consensus appears to be over-penalizing the pre-market drawdown as if it were a one-quarter miss. The stock looks more like a 2-3 quarter re-rating event: if management can keep Jotun’s margin bridge intact and prove that Health’s restructuring is ring-fenced, the current selloff may become a better entry point later in the year. But right now the asymmetry favors waiting for evidence that the cost shock is controllable rather than trying to catch the falling knife.

Key Decisions for Investors

• Short-term: stay underweight/short ORKLA ASA (or Orkla L) into Q2 print risk; use a 1-3 month horizon because the next leg is likely margin compression rather than revenue weakness.
• If available, pair long JOTUN against short a European branded consumer/staples basket exposed to packaging/energy/freight inflation; the trade benefits from Jotun’s stronger pricing power and better FX absorption over 3-6 months.
• Buy downside protection on ORKLA around the next 1-2 earnings windows (3-6 month puts or put spreads) to monetize the mismatch between delayed cost pass-through and improving volume optics.
• For investors with a longer horizon, begin scaling into ORKLA only on further weakness if management confirms Health restructuring costs are ring-fenced and not contaminating group cash flow; target a 6-12 month recovery trade.
• Avoid chasing the post-print bounce in consumer-goods peers with similar input-cost exposure until there is evidence the cost shock is transitory; the better risk/reward is in names with explicit pricing power or energy pass-through.